CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

Gerard M Walls; Jamie B Oughton; Anthony J Chalmers; Sarah Brown; Fiona Collinson; Martin D Forster; Kevin N Franks; Alexandra Gilbert; Gerard G Hanna; Nicola Hannaway; Stephen Harrow; Tom Haswell; Crispin T Hiley; Samantha Hinsley; Matthew Krebs; Geraldine Murden; Rachel Phillip; Anderson J Ryan; Ahmed Salem; David Sebag-Montefoire; Paul Shaw; Chris J Twelves; Katrina Walker; Robin J Young; Corinne Faivre-Finn; Alastair Greystoke

doi:10.1016/j.ctro.2020.09.006

CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

Gerard M Walls, Jamie B Oughton, Anthony J Chalmers, Sarah Brown, Fiona Collinson, Martin D Forster, Kevin N Franks, Alexandra Gilbert, Gerard G Hanna, Nicola Hannaway, Stephen Harrow, Tom Haswell, Crispin T Hiley, Samantha Hinsley, Matthew Krebs, Geraldine Murden, Rachel Phillip, Anderson J Ryan, Ahmed Salem, David Sebag-MontefoirePaul Shaw, Chris J Twelves, Katrina Walker, Robin J Young, Corinne Faivre-Finn, Alastair Greystoke

School of Medicine, Dentistry and Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

146 Downloads (Pure)

Abstract

Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for 'gold standard' treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.

Original language	English
Pages (from-to)	61-66
Number of pages	6
Journal	Clinical and Translational Radiation Oncology
Volume	25
Early online date	22 Sep 2020
DOIs	https://doi.org/10.1016/j.ctro.2020.09.006
Publication status	Early online date - 22 Sep 2020

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ctro.2020.09.006Licence: CC BY

CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer
Copyright 2020 the authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
Final published version, 879 KBLicence: CC BY

Cite this

Walls, G. M., Oughton, J. B., Chalmers, A. J., Brown, S., Collinson, F., Forster, M. D., Franks, K. N., Gilbert, A., Hanna, G. G., Hannaway, N., Harrow, S., Haswell, T., Hiley, C. T., Hinsley, S., Krebs, M., Murden, G., Phillip, R., Ryan, A. J., Salem, A., ... Greystoke, A. (2020). CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. Clinical and Translational Radiation Oncology, 25, 61-66. https://doi.org/10.1016/j.ctro.2020.09.006

Walls, Gerard M ; Oughton, Jamie B ; Chalmers, Anthony J ; Brown, Sarah ; Collinson, Fiona ; Forster, Martin D ; Franks, Kevin N ; Gilbert, Alexandra ; Hanna, Gerard G ; Hannaway, Nicola ; Harrow, Stephen ; Haswell, Tom ; Hiley, Crispin T ; Hinsley, Samantha ; Krebs, Matthew ; Murden, Geraldine ; Phillip, Rachel ; Ryan, Anderson J ; Salem, Ahmed ; Sebag-Montefoire, David ; Shaw, Paul ; Twelves, Chris J ; Walker, Katrina ; Young, Robin J ; Faivre-Finn, Corinne ; Greystoke, Alastair. / CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. In: Clinical and Translational Radiation Oncology. 2020 ; Vol. 25. pp. 61-66.

@article{7a8b2ae9083a4970a3aacc71031461f1,

title = "CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer",

abstract = "Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for 'gold standard' treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.",

author = "Walls, {Gerard M} and Oughton, {Jamie B} and Chalmers, {Anthony J} and Sarah Brown and Fiona Collinson and Forster, {Martin D} and Franks, {Kevin N} and Alexandra Gilbert and Hanna, {Gerard G} and Nicola Hannaway and Stephen Harrow and Tom Haswell and Hiley, {Crispin T} and Samantha Hinsley and Matthew Krebs and Geraldine Murden and Rachel Phillip and Ryan, {Anderson J} and Ahmed Salem and David Sebag-Montefoire and Paul Shaw and Twelves, {Chris J} and Katrina Walker and Young, {Robin J} and Corinne Faivre-Finn and Alastair Greystoke",

note = "{\textcopyright} 2020 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.",

year = "2020",

month = sep,

day = "22",

doi = "10.1016/j.ctro.2020.09.006",

language = "English",

volume = "25",

pages = "61--66",

journal = "Clinical and Translational Radiation Oncology",

issn = "2405-6308",

publisher = "Elsevier Ireland Ltd",

}

Walls, GM, Oughton, JB, Chalmers, AJ, Brown, S, Collinson, F, Forster, MD, Franks, KN, Gilbert, A, Hanna, GG, Hannaway, N, Harrow, S, Haswell, T, Hiley, CT, Hinsley, S, Krebs, M, Murden, G, Phillip, R, Ryan, AJ, Salem, A, Sebag-Montefoire, D, Shaw, P, Twelves, CJ, Walker, K, Young, RJ, Faivre-Finn, C & Greystoke, A 2020, 'CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer', Clinical and Translational Radiation Oncology, vol. 25, pp. 61-66. https://doi.org/10.1016/j.ctro.2020.09.006

CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. / Walls, Gerard M; Oughton, Jamie B; Chalmers, Anthony J; Brown, Sarah; Collinson, Fiona; Forster, Martin D; Franks, Kevin N; Gilbert, Alexandra; Hanna, Gerard G; Hannaway, Nicola; Harrow, Stephen; Haswell, Tom; Hiley, Crispin T; Hinsley, Samantha; Krebs, Matthew; Murden, Geraldine; Phillip, Rachel; Ryan, Anderson J; Salem, Ahmed; Sebag-Montefoire, David; Shaw, Paul; Twelves, Chris J; Walker, Katrina; Young, Robin J; Faivre-Finn, Corinne; Greystoke, Alastair.

In: Clinical and Translational Radiation Oncology, Vol. 25, 22.09.2020, p. 61-66.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

AU - Walls, Gerard M

AU - Oughton, Jamie B

AU - Chalmers, Anthony J

AU - Brown, Sarah

AU - Collinson, Fiona

AU - Forster, Martin D

AU - Franks, Kevin N

AU - Gilbert, Alexandra

AU - Hanna, Gerard G

AU - Hannaway, Nicola

AU - Harrow, Stephen

AU - Haswell, Tom

AU - Hiley, Crispin T

AU - Hinsley, Samantha

AU - Krebs, Matthew

AU - Murden, Geraldine

AU - Phillip, Rachel

AU - Ryan, Anderson J

AU - Salem, Ahmed

AU - Sebag-Montefoire, David

AU - Shaw, Paul

AU - Twelves, Chris J

AU - Walker, Katrina

AU - Young, Robin J

AU - Faivre-Finn, Corinne

AU - Greystoke, Alastair

PY - 2020/9/22

Y1 - 2020/9/22

N2 - Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for 'gold standard' treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.

AB - Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for 'gold standard' treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.

U2 - 10.1016/j.ctro.2020.09.006

DO - 10.1016/j.ctro.2020.09.006

M3 - Article

C2 - 33072895

VL - 25

SP - 61

EP - 66

JO - Clinical and Translational Radiation Oncology

JF - Clinical and Translational Radiation Oncology

SN - 2405-6308

ER -

CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

Abstract

Bibliographical note

UN SDGs

Access to Document

Fingerprint

Cite this